24th April 2021, Expert Meeting, Professors Grigoriadis and Boyko gave an update to the slide deck on the role of the microbiome in multiple sclerosis. They discuss the function of the microbiome, its importance in the health of the individual, and how its dysregulation is implicated in altered immune responses in MS.
This video interview with Nikolaos Grigoriadis is based on the slide deck “The Microbiome in Multiples Sclerosis” and brings out the key points. Consult here the video interview.
ABSTRACT
The human microbiome consists of microbes that co-exist in the human body, usually in a symbiotic or mutually beneficial manner. This host-microbiome interaction is highly complex and can become dysregulated, as has been observed in multiple sclerosis (MS) patients. In this presentation, Professors Grigoriadis and Boyko discuss the function of the microbiome, its importance in the health of the individual, and how its dysregulation is implicated in altered immune responses in MS. They also discuss how some currently approved disease-modifying therapies may alter the microbiome, and consider future directions for research on the role of the microbiome in MS.
QUESTIONS ASKED IN THE INTERVIEW
- Can you explain to us what is meant by the term “microbiome”?
- How is the microbiome relevant to multiple sclerosis?
- What are the key take-away points that you would like people to understand from your presentation?
- Is “dysbiosis” or an altered gut microbiome in MS being taken sufficiently seriously by the scientific / medical community?
- How might the gut microbiome influence T and B cell recruitment in autoimmune diseases like MS?
- Can you tell us a little about the gut-brain-axis?
- Do disease-modifying therapies have a positive or negative impact on the microbiome?
- Where does the field head from here? What key questions need to be addressed?
BIOGRAPHY
NIKOLAOS GRIGORIADIS
Nikolaos Grigoriadis graduated from the Faculty of Medicine of the Aristotle University of Thessaloniki. He did his PhD thesis and residency in Neurology in the same institution. He has been specialized in clinical and experimental Neuroimmunology and CNS immunopathology in a number of research centers and institutions abroad. He is now Professor of Neurology at the Aristotle University of Thessaloniki and Head of the of the B’ Dept of Neurology, AHEPA University Hospital, the MS Centre and the Laboratory of Experimental Neurology and Neuroimmunology (www.neuroimmunology.gr). Professor Grigoriadis is member of various international scientific committees such as the European School of Neuroimmunology, ParadigMS, the subcommittee of ENS for Multiple Sclerosis, the ECTRIMS committee (until 2010), Co-founder and Secretary of the Hellenic Academy of Neuroimmunology (www.helani.gr). He is President of the Hellenic Neurological Society. He is Ad Hoc reviewer in more than 40 international scientific journals, co-Ordinator in more than 40 multicenter clinical trials for MS and principal investigator in collaborative research projects for experimental cell therapies in CNS autoimmune demyelination. His field of interests are: Neuroimmunology; Multiple sclerosis; experimental models of autoimmune diseases (EAE etc); neurodegeneration; immunomodulation; cell therapies. He has published more than 180 papers in peer reviewed journals. He has been awarded several times for his scientific work.
Media
